Recently, the results of a phase II clinical trial (NCT00949702) indicated that vemurafenib induces clinical responses in greater than 50% of previously treated mutant BRAF (V600E or V600K) melanoma patients the median overall survival was approximately 16 months [41]. The gene discussed is BRAF; the disease is melanoma.